Press Releases :: Aurinia Pharmaceuticals Inc. (AUPH)

November 16, 2016 • 8:00 am EST

Aurinia Highlights Speed of Remission from Global Phase IIb AURA Study of Voclosporin in Lupus Nephritis at 2016 American College of Rheumatology Annual Meeting

November 10, 2016 • 1:35 pm EST

Aurinia Pharmaceuticals to Present at Stifel 2016 Healthcare Conference

November 9, 2016 • 5:05 pm EST

Aurinia Establishes At-The-Market Facility

November 4, 2016 • 6:55 pm EDT

Aurinia Reports Third Quarter 2016 Financial Results and Operational Highlights

November 2, 2016 • 4:42 pm EDT

Aurinia Announces Plans for Single Phase III Clinical Trial for Voclosporin in the Treatment of Lupus Nephritis Following Successful Completion of End of Phase II Meeting With FDA

October 24, 2016 • 5:15 pm EDT

Aurinia Announces Acceptance of Late-Breaking Voclosporin Abstracts for Oral Presentation at Upcoming Medical Meetings

October 11, 2016 • 8:00 am EDT

Aurinia Pharmaceuticals to Present at the 2016 BIO Investor Forum in San Francisco on October 18, 2016

October 6, 2016 • 8:00 am EDT

Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates over Time for Voclosporin in the Treatment of Lupus Nephritis

September 29, 2016 • 4:54 pm EDT

Aurinia Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints in Its Phase IIb AURA-LV Study for Lupus Nephritis (LN)

September 22, 2016 • 8:00 am EDT

Aurinia Pharmaceuticals to Present at the Leerink Partners Roundtable Series in New York September 28, 2016

Select a page:

rss_feed News RSS

©2025 Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23